

SUPPLEMENTARY DATA

Supplementary Table S1. Dose-response and exposure-response parameters.

Talazoparib parameter	A ₀	I _{max}	ID ₅₀ /IAUC ₅₀	h
Dose (mg)	300	0.950	0.0331	0.865
AUC ₀₋₂₄ (pg·hr/mL)	242	0.978	19,000	1.23

Abbreviations: A₀, estimated baseline activity; AUC₀₋₂₄, area under the plasma concentration-time curve from 0 to 24 h; ID₅₀, inhibitory dose 50%; IAUC₅₀, area under the curve at 50% of inhibition; I_{max}, maximum inhibitory effect; PARP, poly(ADP-ribose) polymerase; PBMC, peripheral blood mononuclear cell.

As illustrated in the dose-response curve, a fair degree of variability was observed across patients at doses of 0.4 mg/day and below, with near complete inhibition being achieved in one patient at 0.1 mg/day and all three patients at 0.2 mg/day dose levels, while two of the three patients at the 0.4 mg/day dose level showed little inhibition. PBMC PARP inhibition was consistently inhibited across all patients at doses of 0.6 mg/day and above with an IC₅₀ of 0.0331 mg/day.